RBC Capital: 'Takeout Analysis Suggests BCRX Shares Still Undervalued'

March 25, 2026 6:11 AM

RBC Capital analyst Brian Abraham reiterated an Outperform rating and $13.00 price target on BioCryst Pharma (NASDAQ: BCRX)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found